Race Oncology

Home

Announcements

Governance

Updates

Inter

RAC.AX - Protecting the Heart Fighting the Disease Bisantrenes Dual Action (093024).pdf

MST Access Senior Life Sciences Analyst Chris Kallos published the latest research report on Race Oncology, noting an improved valuation of the company at A$6.37 (prev. A$3.22) based on three key highlights post Race's full year reporting:

Bisantrene is the enabler for higher dosing of anthracyclines

RC220 to enter human clinical trials in 2HCY24

FY24 result and cash on hand – fully funded for current programs

Read the full report below, and leave your comments and questions in the discussion section to interact with RAC's management team. 